Retifanlimab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Merkel Cell Carcinoma
Conditions
Metastatic Merkel Cell Carcinoma
Trial Timeline
Feb 25, 2019 → Jun 28, 2024
NCT ID
NCT03599713About Retifanlimab
Retifanlimab is a phase 2 stage product being developed by Incyte for Metastatic Merkel Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03599713. Target conditions include Metastatic Merkel Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Merkel Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06910137 | Pre-clinical | Active |
| NCT04231981 | Phase 2 | Completed |
| NCT03599713 | Phase 2 | Completed |
| NCT03679767 | Phase 2 | Completed |
| NCT03597295 | Phase 2 | Completed |
| NCT03059823 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Merkel Cell Carcinoma